Showing 821 - 840 results of 1,915 for search '"cancer"', query time: 0.06s Refine Results
  1. 821
  2. 822
  3. 823
  4. 824
  5. 825

    Lumbosacral Plexopathy After Carbon-ion Radiation Therapy for Postoperative Pelvic Recurrence of Rectal Cancer: Subanalysis of a Prospective Observational Study (GUNMA 0801) by Takuya Kumazawa, MD, PhD, Shintaro Shiba, MD, PhD, Yuhei Miyasaka, MD, PhD, Masahiko Okamoto, MD, PhD, Daijiro Kobayashi, MD, PhD, Tatsuya Ohno, MD, PhD

    Published 2025-03-01
    “…Purpose: Data are lacking on the risk factors for radiation-induced lumbosacral plexopathy (RILSP) after carbon-ion radiation therapy (CIRT) for pelvic tumors, such as postoperative recurrence of rectal cancer. We investigated the incidence of RILSP and the associated dosimetric parameters using data from a prospective study of CIRT for postoperative pelvic recurrence of rectal cancer (GUNMA 0801). …”
    Get full text
    Article
  6. 826

    The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis by Edward Li, Bridgette Kanz Schroader, David Campbell, Kim Campbell, Weijia Wang

    Published 2021-06-01
    “…**Methods:** This was a retrospective observational study in patients with breast cancer (BC) who received myelosuppressive chemotherapy and prophylactic pegfilgrastim identified January 1, 2017-May 31, 2018 from MarketScan® research databases. …”
    Get full text
    Article
  7. 827

    Curcumin inhibits growth and triggers apoptosis in human castration-resistant prostate cancer cells via IGF-1/PI3K/Akt pathway by Chao Chen, Qiwu Wang, Jiwen Liu

    Published 2025-02-01
    “…Objective This study aimed to investigate the possible mechanism by which curcumin inhibits human prostate cancer (PCa) and castration-resistant prostate cancer (CRPC). …”
    Get full text
    Article
  8. 828

    Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial by Guoshuang Shen, Zhilin Liu, Miaozhou Wang, Yi Zhao, Xinlan Liu, Yujin Hou, Wenbiao Ma, Jingqi Han, Xiaofeng Zhou, Dengfeng Ren, Fuxing Zhao, Zitao Li, Shifen Huang, Yongzhi Chen, Yingjian He, Yan Liu, Zijun Zhu, Yongxin Li, Jinming Li, Mengting Da, Hongnan Mo, Feng Du, Liang Cui, Jing Bai, Zhen Liu, Fei Ma, Jiuda Zhao

    Published 2025-02-01
    “…Abstract We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative breast cancer (TNBC). In the phase 2 NeoSAC trial, patients with early TNBC received six cycles of apatinib, sintilimab, nab-paclitaxel, and carboplatin followed by surgery. …”
    Get full text
    Article
  9. 829
  10. 830
  11. 831
  12. 832
  13. 833
  14. 834
  15. 835
  16. 836
  17. 837
  18. 838
  19. 839
  20. 840